Instrument Inactif

Autres langues Acorda Therapeutics, Inc.

Actions

ACOR.Q

US00484M7002

Recherche biotechnologique et médicale

Autres langues

06/08/25	Federal Circuit Denies Appellate Jurisdiction Based On Alternative Ground For Relief
13/08/24	First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.
09/08/24	Acorda Therapeutics : UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK Form 8 K
07/08/24	Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc.
30/07/24	First Motion for Exclusivity Period Extension Filed by Acorda Therapeutics, Inc.
11/07/24	Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
10/07/24	Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.
03/07/24	Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.
01/07/24	First Amended Joint Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.
12/06/24	Motion for Asset Sale Approved for Acorda Therapeutics, Inc.
14/05/24	Acorda: Q1 Earnings Snapshot
14/05/24	Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
10/05/24	Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.
03/05/24	Final DIP Financing Approved for Acorda Therapeutics, Inc.
29/04/24	Bidding Procedure Approved for Acorda Therapeutics, Inc.
15/04/24	Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market
15/04/24	Acorda Therapeutics Announces Delisting from Nasdaq
05/04/24	Interim DIP Financing Approved for Acorda Therapeutics, Inc.
05/04/24	Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from S&P TMI Index
01/04/24	Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.